Medivir in brief

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.

The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.

Medivir is listed on the Nasdaq Stockholm Mid Cap List.


Page updated 15 May 2017